Table 1.
Design, setting, and participants information in CATIS study and the present study
| Variables | Information |
|---|---|
| CATIS study | |
| Participants and participating hospitals | A multicenter, single-blind, blinded end-points randomized clinical trial in 26 hospitals across China (n = 4071) |
| Brief introduction | In the CATIS study, 4071 patients with an adjudicated diagnosis of ischemic stroke by computed tomography or magnetic resonance imaging of the brain within 48 hours after symptom onset were recruited from August 2009 to May 2013. |
| Inclusion criteria | 1. Age ≥ 22 years 2. Having ischemic stroke confirmed by computed tomography or magnetic resonance imaging of the brain within 48 h of symptom onset 3. Having an elevated systolic blood pressure between 140 and 220 mmHg |
| Exclusion criteria | 1. Having a systolic blood pressure ≥ 220 mmHg or diastolic blood pressure ≥ 120 mmHg 2. Having severe heart failure, acute myocardial infarction, unstable angina, atrial fibrillation, aortic dissection, cerebrovascular stenosis, resistant hypertension, and deep coma 3. Having been treated with intravenous thrombolytic therapy |
| Pre-planned ancillary study based on CATIS | |
| Patients selection | CATIS trial participants were systemically selected prior to randomization from seven participating hospitals for cognitive function assessment at their 3-month follow-up visit. Eighty to 100 patients were recruited consecutively from each participating hospitals and the recruitment was completed by November 2012. A total of 660 patients were included in the pre-planned ancillary study. |
| Loss to follow-up | At the 3-month visit, 15 patients were lost to follow-up and 7 patients were deceased. A total of 638 participants who completed the cognitive function tests at 3 months were included in the present analysis. |
| Failed to test cystatin C | A total of 56 patients refused to offer blood samples and some collected samples were hemolyzed in storage or transport, a total of 582 participants were finally included in the present analysis. |
CATIS: China Antihypertensive Trial in Acute Ischemic Stroke (He et al., 2014; Bu et al., 2016).